Arcturus Therapeutics Holdings, Inc.
Arcturus Therapeutics is a global leader in developing innovative mRNA medicines and vaccines, with a focus on infectious disease vaccines and rare liver and respiratory diseases. The company leverages proprietary technologies such as LUNAR® lipid-mediated delivery, STARR® mRNA technology, and extensive patent portfolios to create versatile RNA therapeutics. With a multicultural team based in San Diego, CA, Arcturus aims to advance the next generation of mRNA medicines to address unmet medical needs and improve patient outcomes.
Industries
Nr. of Employees
medium (51-250)
Arcturus Therapeutics Holdings, Inc.
San Diego, California, United States, North America
Products
Self‑amplifying mRNA COVID‑19 vaccine (clinically evaluated and authorized in select jurisdictions)
A self‑amplifying RNA vaccine candidate evaluated in multiple clinical trials demonstrating immunogenicity, durable neutralizing antibody responses and efficacy against severe disease; authorized in some markets.
LNP‑encapsulated mRNA therapeutics for hepatic enzyme replacement
Systemically delivered LNP‑mRNA candidates encoding functional hepatic enzymes to restore plasma and liver enzyme activity in models of metabolic deficiency (examples include OTC and PKU models).
Aerosolized LNP‑encapsulated mRNA replacement therapy for pulmonary disease
Nebulized LNP‑mRNA formulations designed for inhalation delivery to airway epithelial cells to restore protein function and improve mucociliary clearance in preclinical and early clinical studies for cystic fibrosis and other pulmonary genetic diseases.
LNP‑mediated mRNA platform for gene editing and diverse RNA modalities
Platform applications delivering mRNAs encoding gene‑editing nucleases or functional RNAs (suppressor tRNAs, siRNAs, enzyme mRNAs) for in vivo gene disruption, nonsense mutation suppression or enzyme replacement across multiple disease models.
Self‑amplifying mRNA COVID‑19 vaccine (clinically evaluated and authorized in select jurisdictions)
A self‑amplifying RNA vaccine candidate evaluated in multiple clinical trials demonstrating immunogenicity, durable neutralizing antibody responses and efficacy against severe disease; authorized in some markets.
LNP‑encapsulated mRNA therapeutics for hepatic enzyme replacement
Systemically delivered LNP‑mRNA candidates encoding functional hepatic enzymes to restore plasma and liver enzyme activity in models of metabolic deficiency (examples include OTC and PKU models).
Aerosolized LNP‑encapsulated mRNA replacement therapy for pulmonary disease
Nebulized LNP‑mRNA formulations designed for inhalation delivery to airway epithelial cells to restore protein function and improve mucociliary clearance in preclinical and early clinical studies for cystic fibrosis and other pulmonary genetic diseases.
LNP‑mediated mRNA platform for gene editing and diverse RNA modalities
Platform applications delivering mRNAs encoding gene‑editing nucleases or functional RNAs (suppressor tRNAs, siRNAs, enzyme mRNAs) for in vivo gene disruption, nonsense mutation suppression or enzyme replacement across multiple disease models.
Services
Partnered development and licensing for RNA programs
Co‑development and licensing collaborations to advance RNA vaccine and therapeutic programs, combining mRNA design, delivery and regulatory support with external partners and commercialization partners.
Manufacturing partnerships and technology transfer
Support for establishing or expanding RNA manufacturing capacity and transferring CMC, LNP formulation and drug product processes to contract manufacturers or local sites.
Clinical development and trial execution for RNA therapeutics
End‑to‑end clinical trial services for RNA therapeutics and vaccines including protocol design, multi‑center trial operations, biomarker and immunogenicity assessment, and regulatory submission support.
Partnered development and licensing for RNA programs
Co‑development and licensing collaborations to advance RNA vaccine and therapeutic programs, combining mRNA design, delivery and regulatory support with external partners and commercialization partners.
Manufacturing partnerships and technology transfer
Support for establishing or expanding RNA manufacturing capacity and transferring CMC, LNP formulation and drug product processes to contract manufacturers or local sites.
Clinical development and trial execution for RNA therapeutics
End‑to‑end clinical trial services for RNA therapeutics and vaccines including protocol design, multi‑center trial operations, biomarker and immunogenicity assessment, and regulatory submission support.
Expertise Areas
- mRNA vaccine and self‑amplifying RNA (saRNA) development
- mRNA design for protein replacement and gene modulation
- Lipid nanoparticle delivery engineering and ionizable lipid chemistry
- Pulmonary/inhaled delivery of nucleic acid therapeutics
Key Technologies
- Self‑amplifying/replicon RNA platforms
- Conventional mRNA therapeutics
- Lipid nanoparticle (LNP) delivery systems
- Ionizable cationic lipid chemistry and property‑driven lipid design